Afatinib
English name: Afatinib
CAS: 439081-18-2
Purity: 99%
Molecular formula: C24H25ClFN5O3
Molecular weight: 485.94
EINECS number: 1308068-626-2
CAS: 439081-18-2
Purity: 99%
Molecular formula: C24H25ClFN5O3
Molecular weight: 485.94
EINECS number: 1308068-626-2
C290
Quantity
Inhibiting tumor growth: Afatinib blocks the growth and spread of cancer cells by inhibiting the activity of the epidermal growth factor receptor (EGFR) family, thereby slowing down the development of tumors.
Treatment of NSCLC: Afatinib is widely used to treat EGFR mutation-positive advanced or metastatic non-small cell lung cancer, which can prolong patients' survival time and improve their quality of life.
Treatment of metastatic gastric cancer: Afatinib is also used to treat metastatic gastric cancer, especially in patients with EGFR overexpression, to slow the progression of the disease and improve patient survival rates.
Personalized treatment: Afatinib is a personalized treatment drug that selects treatment options based on the patient's genotype and molecular biomarkers to improve efficacy and reduce adverse reactions.
Treatment of NSCLC: Afatinib is widely used to treat EGFR mutation-positive advanced or metastatic non-small cell lung cancer, which can prolong patients' survival time and improve their quality of life.
Treatment of metastatic gastric cancer: Afatinib is also used to treat metastatic gastric cancer, especially in patients with EGFR overexpression, to slow the progression of the disease and improve patient survival rates.
Personalized treatment: Afatinib is a personalized treatment drug that selects treatment options based on the patient's genotype and molecular biomarkers to improve efficacy and reduce adverse reactions.
Afatinib is usually used to treat non-small cell lung cancer or stomach cancer that has spread to other sites.
